ID

29220

Descripción

Effect of Liraglutide or Glimepiride Added to Metformin on Blood Glucose Control in Subjects With Type 2 Diabetes; ODM derived from: https://clinicaltrials.gov/show/NCT00614120

Link

https://clinicaltrials.gov/show/NCT00614120

Palabras clave

Versiones (1)
  1. 8/3/18 8/3/18 -
Titular de derechos de autor

See clinicaltrials.gov

Subido en

8 de marzo de 2018

DOI

Para solicitar uno, por favor iniciar sesión.

Licencia

Creative Commons BY 4.0
Comentarios del modelo :

Puede comentar sobre el modelo de datos aquí. A través de las burbujas de diálogo en los grupos de elementos y elementos, puede agregar comentarios específicos.

Volver a los comentarios del modelo
Comentarios de grupo de elementos para :

Comentarios del elemento para :

Para descargar modelos de datos, debe haber iniciado sesión. Por favor iniciar sesión o Registrate gratis.

Eligibility Diabetes NCT00614120

Inglés

Eligibility Diabetes NCT00614120

1 formularios  
  1. StudyEvent: Eligibility
    1. Eligibility Diabetes NCT00614120
Inclusion Criteria
Descripción

Inclusion Criteria

Alias
UMLS CUI
C1512693
type 2 diabetes
Descripción

Diabetes Mellitus, Non-Insulin-Dependent

Tipo de datos

boolean

Alias
UMLS CUI [1]
C0011860
subjects diagnosed with type 2 diabetes and treated with one or more oral antidiabetic drugs (oads) for the last 3 months
Descripción

Diabetes Mellitus, Non-Insulin-Dependent | Antidiabetics Oral Quantity

Tipo de datos

boolean

Alias
UMLS CUI [1]
C0011860
UMLS CUI [2,1]
C0935929
UMLS CUI [2,2]
C1527415
UMLS CUI [2,3]
C1265611
hba1c: 7.0-11.0% (both incl.) for subjects on oad alone
Descripción

Glucohemoglobin measurement | Antidiabetics Oral Alone

Tipo de datos

boolean

Alias
UMLS CUI [1]
C0202054
UMLS CUI [2,1]
C0935929
UMLS CUI [2,2]
C1527415
UMLS CUI [2,3]
C0205171
hba1c: 7.0-10.0 % (both incl.) for subjects on oad combination therapy
Descripción

Glucohemoglobin measurement | Antidiabetics Oral | Combined Modality Therapy

Tipo de datos

boolean

Alias
UMLS CUI [1]
C0202054
UMLS CUI [2,1]
C0935929
UMLS CUI [2,2]
C1527415
UMLS CUI [3]
C0009429
bmi less than 45.0 kg/m^2
Descripción

Body mass index

Tipo de datos

boolean

Alias
UMLS CUI [1]
C1305855
Exclusion Criteria
Descripción

Exclusion Criteria

Alias
UMLS CUI
C0680251
treatment with insulin within the last 3 months prior to the trial
Descripción

Insulin regime

Tipo de datos

boolean

Alias
UMLS CUI [1]
C0557978
impaired liver or/and renal function
Descripción

Liver Dysfunction | Renal Insufficiency

Tipo de datos

boolean

Alias
UMLS CUI [1]
C0086565
UMLS CUI [2]
C1565489
significant cardiovascular disease over the last 6 months
Descripción

Cardiovascular Disease Disease length

Tipo de datos

boolean

Alias
UMLS CUI [1,1]
C0007222
UMLS CUI [1,2]
C0872146
known retinopathy or maculopathy
Descripción

Retinal Disease | Disorder of macula of retina

Tipo de datos

boolean

Alias
UMLS CUI [1]
C0035309
UMLS CUI [2]
C0730362
recurrent major hypoglycaemia or hypoglycaemic unawareness
Descripción

Recurrent severe hypoglycemia | Loss of hypoglycemic warning

Tipo de datos

boolean

Alias
UMLS CUI [1]
C0342316
UMLS CUI [2]
C0342317
Volver a la parte superior de la página

Similar models

Eligibility Diabetes NCT00614120

1 formularios
  1. StudyEvent: Eligibility
    1. Eligibility Diabetes NCT00614120
Name
Tipo
Description | Question | Decode (Coded Value)
Tipo de datos
Alias
Item Group
C1512693 (UMLS CUI)
Diabetes Mellitus, Non-Insulin-Dependent
Item
type 2 diabetes
boolean
C0011860 (UMLS CUI [1])
Diabetes Mellitus, Non-Insulin-Dependent | Antidiabetics Oral Quantity
Item
subjects diagnosed with type 2 diabetes and treated with one or more oral antidiabetic drugs (oads) for the last 3 months
boolean
C0011860 (UMLS CUI [1])
C0935929 (UMLS CUI [2,1])
C1527415 (UMLS CUI [2,2])
C1265611 (UMLS CUI [2,3])
Glucohemoglobin measurement | Antidiabetics Oral Alone
Item
hba1c: 7.0-11.0% (both incl.) for subjects on oad alone
boolean
C0202054 (UMLS CUI [1])
C0935929 (UMLS CUI [2,1])
C1527415 (UMLS CUI [2,2])
C0205171 (UMLS CUI [2,3])
Glucohemoglobin measurement | Antidiabetics Oral | Combined Modality Therapy
Item
hba1c: 7.0-10.0 % (both incl.) for subjects on oad combination therapy
boolean
C0202054 (UMLS CUI [1])
C0935929 (UMLS CUI [2,1])
C1527415 (UMLS CUI [2,2])
C0009429 (UMLS CUI [3])
Body mass index
Item
bmi less than 45.0 kg/m^2
boolean
C1305855 (UMLS CUI [1])
Item Group
C0680251 (UMLS CUI)
Insulin regime
Item
treatment with insulin within the last 3 months prior to the trial
boolean
C0557978 (UMLS CUI [1])
Liver Dysfunction | Renal Insufficiency
Item
impaired liver or/and renal function
boolean
C0086565 (UMLS CUI [1])
C1565489 (UMLS CUI [2])
Cardiovascular Disease Disease length
Item
significant cardiovascular disease over the last 6 months
boolean
C0007222 (UMLS CUI [1,1])
C0872146 (UMLS CUI [1,2])
Retinal Disease | Disorder of macula of retina
Item
known retinopathy or maculopathy
boolean
C0035309 (UMLS CUI [1])
C0730362 (UMLS CUI [2])
Recurrent severe hypoglycemia | Loss of hypoglycemic warning
Item
recurrent major hypoglycaemia or hypoglycaemic unawareness
boolean
C0342316 (UMLS CUI [1])
C0342317 (UMLS CUI [2])
Volver a la parte superior de la página 

Contacto

Utilice este formulario para comentarios, preguntas y sugerencias.

Los campos marcados con * son obligatorios.

Ayuda

Do you need help on how to use the search function? Please watch the corresponding tutorial video for more details and learn how to use the search function most efficiently.

Watch Tutorial